Passaia, Bárbara dos Santos; Lima, Keli 
; Kremer, Jean Lucas ; Conceição, Barbara Brito da ; Mariani, Beatriz Marinho de Paula ; Silva, Jean Carlos Lipreri da ; Zerbini, Maria Claudia Nogueira ; Fragoso, Maria Candida Barisson Villares ; Machado Neto, João Agostinho ; Lotfi, Claudimara Ferini Pacicco
Fonte: Investigational New Drugs. Unidades: FM, ICB
Assuntos: ANATOMIA, FARMACOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, CARCINOMA, NEOPLASIA ENDÓCRINA MÚLTIPLA, MICROTÚBULOS, FENÓTIPOS, CLONAGEM, ONCOPROTEÍNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PASSAIA, Bárbara dos Santos et al. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours. Investigational New Drugs, v. 38, p. 899–908, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10637-019-00846-9. Acesso em: 05 out. 2024.APA
Passaia, B. dos S., Lima, K., Kremer, J. L., Conceição, B. B. da, Mariani, B. M. de P., Silva, J. C. L. da, et al. (2020). Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours. Investigational New Drugs, 38, 899–908. doi:10.1007/s10637-019-00846-9NLM
Passaia B dos S, Lima K, Kremer JL, Conceição BB da, Mariani BM de P, Silva JCL da, Zerbini MCN, Fragoso MCBV, Machado Neto JA, Lotfi CFP. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours [Internet]. Investigational New Drugs. 2020 ; 38 899–908.[citado 2024 out. 05 ] Available from: https://doi.org/10.1007/s10637-019-00846-9Vancouver
Passaia B dos S, Lima K, Kremer JL, Conceição BB da, Mariani BM de P, Silva JCL da, Zerbini MCN, Fragoso MCBV, Machado Neto JA, Lotfi CFP. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours [Internet]. Investigational New Drugs. 2020 ; 38 899–908.[citado 2024 out. 05 ] Available from: https://doi.org/10.1007/s10637-019-00846-9
